GlassScriptPhysician profile
Philip N Johnson
NPI 1811913866
$3,160.66
in general payments reported to CMS, 2019-2025
36 companies · $576 in 2025
The $576 reported for 2025 was more than what 83% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $276 · 2020: $66.29 · 2021: $248 · 2022: $569 · 2023: $485 · 2024: $941 · 2025: $576.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,208 · Travel and Lodging: $714 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,207.92 |
| Travel and Lodging | $714.13 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Applied Medical Resources Corporation | $689.59 | 2024 | Gelpoint V-Path |
| Abbvie INC. | $554.30 | 2019-2023 | |
| Medical Device Business Services, INC. | $333.24 | 2025 | Harmonic |
| Astellas Pharma US INC | $175.39 | 2023-2024 | Veozah |
| Sumitomo Pharma America, INC. | $118.18 | 2023-2024 | Myfembree |
| Myovant Sciences INC. | $105.85 | 2021-2022 | |
| Therapeuticsmd, INC. | $105.06 | 2019-2022 | |
| Intuitive Surgical, INC. | $95.86 | 2025 | |
| Baxter Healthcare | $82.68 | 2025 | Tisseel, Perclot, Floseal |
| Agile Therapeutics, INC. | $78.81 | 2021-2024 | Twirla |
| Organon LLC | $77.03 | 2021-2024 | Nexplanon |
| Ethicon US, LLC | $75.94 | 2020-2025 | Surgiflo Hemostatic Matrix |
| Pfizer INC. | $69.67 | 2021-2023 | |
| Millicent US INC | $56.09 | 2022-2023 | Femring, Intrarosa |
| Merck Sharp & Dohme LLC | $46.77 | 2019-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $45.86 | 2021-2024 | Slynd |
| Allergan, INC. | $39.55 | 2019 | |
| Minerva Surgical, INC | $35.71 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.94 | 2019-2022 | |
| Insulet Corporation | $34.28 | 2021-2024 | Omnipod |
| Abbott Laboratories | $32.88 | 2019-2022 | |
| Coopersurgical, INC. | $32.85 | 2022-2024 | Paragard T 380a |
| Dysis Medical, INC. | $22.63 | 2023 | Dysis Ultra 2.0, Dysis V3 Digital Coploscope, Dysis View |
| Mayne Pharma Commercial LLC | $22.18 | 2022 | |
| Axonics, INC. | $20.05 | 2024 | Bulkamid, Axonics |
| Hologic Sales and Service, LLC | $19.46 | 2024 | Myosure Tissue Removal Device |
| Mycovia Pharmaceuticals, INC. | $18.69 | 2023 | Vivjoa |
| Shield Therapeutics INC | $18.25 | 2024 | |
| Meditrina | $17.91 | 2024 | |
| Boston Scientific Corporation | $17.85 | 2025 | Bulkamid |
| Mimedx Group, INC. | $15.39 | 2024 | |
| Lupin INC. | $15.21 | 2019 | |
| Gynesonics, INC. | $13.72 | 2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Amgen INC. | $13.37 | 2019 | |
| Medtronic, INC. | $13.28 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $12.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.